

Patient History & Demographics

- Age
- Sex
- Ethnicity
- ECOG at Diagnosis
- Previous Family History of Cancer
- Previous Cancer Diagnosis
- Date of Previous Cancer Diagnosis
- Treatment Received for Previous Cancer
- Family History of Lung Cancer
- History of Genetic testing
- Germline Mutations
- Tumour Morphology (Adenocarcinoma, Squamous Cell Carcinoma, Adenosquamous, Large Cell Undifferentiated, NSCLC not otherwise specified, Neuroendocrine, Small Cell, Carcinoid, Neuroendocrine (other), Mixed NSCLC/SCLC, Mesothelioma, Thymic Carcinoma, Thymoma, Other, Unknown, Biopsy non-diagnostic, Biopsy non-malignant)
- Tobacco Use
- Pack Years
- E-cigarette Use

Clinical Stage at Diagnosis

- Limited vs Extensive stage (small cell lung cancer)
- Clinical TNM Stage (8th Edition)
- Clinical T Stage (8th Edition)
- Clinical N Stage (8th Edition)
- Clinical M Stage (8th Edition)
- Metastatic Disease at Diagnosis
- Site of Metastatic Disease at Diagnosis
- Other Sites of Metastatic Disease

Charlson Comorbidity Index

- Comorbidities

Mutation Testing Summary

- Mutation Testing & Status: ALK, BRAF, EGFR, ERBB2, KRAS, MET, PDL1, PIK3CA, ROS1, Other

Treatment and Response

- Did the Patient Receive Treatment?
- Reason Treatment not Received
- Reason Patient Declined Treatment
- Treatment Type
- Surgery Date
- Facility Surgery Performed
- Intention of Surgery
- Surgery Access Approach Taken
- Type of Surgery Performed
- Surgery Laterality
- Surgical Outcome
- Adjuvant or Neoadjuvant Treatment/s Delivered Alongside Surgery
- Radiotherapy Start Date
- Radiotherapy End Date
- At which Facility was the Radiotherapy Performed?
- Radiotherapy Treatment Setting
- Intention of Radiotherapy
- Type of Radiotherapy Performed
- Site of Radiotherapy
- Metastatic site of Radiotherapy
- Radiotherapy Dose
- Radiotherapy Fractions
- Systemic Treatment Setting
- Intention of Systemic Treatment
- Treatment Line
- Number of Treatment Agents
- Systemic Treatment Agent Details
- Has the Patient Stopped Receiving Systemic Treatment?
- Number of Systemic Treatment Cycles Completed
- Reason it was Stopped
- Did the Patient receive Immunotherapy in this Treatment Line?
- Was the Patient Considered a Responder or Non-responder to Immunotherapy?
- Best Response
- Date of Best Response
- Best Response based on Imaging or Clinician report?
- Imaging used to Determine Best Response
- Was there Recurrent/Progressive Disease
- Date of First Recurrence/Relapse/Progression
- Date of First Recurrence/Relapse/Progression Reflects Date of: Imaging, Clinician Report, Start of new treatment minus one day, Death

- Imaging used to Determine Progression
- Site of First Recurrence/Progression
- Date of CT scan that Identified Progression
- Location of where CT scan was performed
- Date of PET scan that identified progression
- Location of where PET scan was performed
- Date of MRI scan that identified progression
- Location of where MRI scan was performed
- Was this Treatment part of a Clinical Trial?
- Name of Clinical Trial
- Registry Number of Clinical Trial
- Description of Clinical Trial Intervention
- Was the Clinical Trial Intervention Completed?

Immune-related Adverse Events

- Date Toxicity Started
- Date Toxicity Resolved
- Toxicity Type
- Toxicity Grade
- Relationship to Current Treatment
- Action Taken with Treatment

Biobank Blood Samples

- Timepoint Collected: Baseline, Cycle 2 (Day 1), Cycle 4 (Day 1), Pre-Cycle 5 (1st Re-staging Scan), Pre-Cycle 9 (2nd Re-staging Scan), Disease Progression, Other Timepoint
- Was a Blood Sample Collected?
- Was EBUS Sample Collected?
- Number of Sites Collected
- Was the Tissue Site a Tumour or Node?
- Tissue Site Location (if Tumour was Sampled)
- Tissue Site Location (if Node was Sampled)
- Tissue Site Histology
- Tissue Site Tumour Cellularity
- Were Tissue Samples Bioinformatically Analysed?

Follow-up

- Date of Follow up
- Patient Survival Status
- Date of Death
- Cause of Death